ENB Therapeutics
PrivateLast Round
VC Round
Sep 29, 2021
Total Funding Raised
$12M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ENB Therapeutics operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a VC Round in September 2021.
ENB Therapeutics is a biopharmaceutical company that develops small molecule inhibitors targeting the endothelin B receptor to overcome drug resistance in cancer immunotherapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ENB Therapeutics Comparables
Compare ENB Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Helix BioPharma Corp. | 75% | |
| Gmax Biopharm | 74% | |
| Roche Holding | 72% |
For institutional investors. Book with your work email.
ENB Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 29, 2021 | ||||
| Convertible Debt | Feb 18, 2021 | ||||
| Series A | Sep 20, 2018 | ||||
| Seed | Mar 31, 2018 | ||||
| Angel | Dec 31, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ENB Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series A |
| Empire State Development | Series A |
| Alexandria Venture Investments | Series A |
| BioAdvance Capital | Series A, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 41% MoM.
- Jul 24, 2026
Monthly visitors increased 84% MoM.
For institutional investors. Book with your work email.
ENB Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ENB Therapeutics's valuation, stock price, and market status.
Is ENB Therapeutics a public or private company?
ENB Therapeutics is a private company.
What is the current stock price of ENB Therapeutics?
ENB Therapeutics is a private company, so its shares have no public market price. Caplight tracks ENB Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ENB Therapeutics worth (valuation)?
Valuation information for ENB Therapeutics is not publicly available.
Can I buy ENB Therapeutics stock?
ENB Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ENB Therapeutics's last funding round?
ENB Therapeutics's most recent funding round was VC Round on September 29, 2021.
Who are the main investors in ENB Therapeutics?
Key investors in ENB Therapeutics include Remiges Ventures.
Will ENB Therapeutics IPO soon?
No public IPO plans have been announced for ENB Therapeutics.
How can I track ENB Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ENB Therapeutics's shares on secondary markets.